Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.

By D. Burbee, É. Forgács, S. Zöchbauer-Müller, L. Shivakumar, K. Fong, B. Gao, Dwight Randle, M. Kondo, A. Virmani, S. Bader and 9 more. Journal of the National Cancer Institute, 2001

822 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/4e223560b305b92f93a8b77282ba625b629e1386

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Baylin
2. Peter A. Jones
3. A. Maitra
4. Adi F. Gazdar
5. Dan E. Arking
6. Manel Esteller
7. Peter W. Laird
8. A. Bird

In Oncology

1. D. Bar-Sagi
2. Y. Pylayeva-Gupta
3. Peter A. Jones
4. Adi F. Gazdar
5. S. Baylin

Citations in the corpus

• Epigenetic Determinants of Cancer. (2016, background): “Examples include RasFF1a and FHIT, located on chromosome arm 3p, frequently deleted in lung and other types of tumors (Dammann et al. 2000; Burbee et al. 2001).”
• Genomic alterations in cultured human embryonic stem cells (2005, background): “Epigenetic silencing of RASSF1 gene by promoter methylation is a feature of many human cancers, whereas most non-neoplastic cell types are characterized by unmethylated promoter”
• RAS oncogenes: weaving a tumorigenic web (2011, background): “There is an indication that such a pro-apoptotic function of RAS might be selected against in cancer, as the expression of either RASSF1 or RASSF5 in tumours is frequently suppressed either owing to promoter hypermethylation or — in the case of RASSF1 — owing to the deletion of the chromosomal”